Search results
Cantor Fitzgerald sets price target on Skye Bioscience shares By Investing.com
Investing.com· 2 days agoOn Thursday, Cantor Fitzgerald began coverage on Skye Bioscience Inc. (NASDAQ:SKYE), assigning an...
Can ICH Q14 Ease Regulatory Risks Around Impurity And Potency Testing?
BioresearchOnline· 4 days agoRobust and reliable analytical procedures are critical in the life sciences industry. Over the...
Guest opinion: Don't break the life-sciences industry - San Francisco Business Times
The Business Journals· 1 day agoThe last discovery of a new class of antimicrobials that reached the market was in 1987. If...
GAIA HERBS ASHWAGANDHA PRODUCT PURITY
FOX 59 Indianapolis· 13 hours agoFounded almost 40 years ago, Gaia Herbs, a leader in herbal supplements, stands behind the purity and potency of every product and the accuracy of every...
3 Healthcare Mutual Funds to Buy Amid Rate Cut Uncertainty
Zacks via Yahoo Finance· 2 days agoFPHAX advisors use fundamental analysis of factors like each issuer's financial condition and ...
Insider Sale: CEO & President Reshma Kewalramani Sells 15,202 Sh
Guru Focus· 5 days agoOn May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (VRTX, Financial), executed a sale of 15,202 shares of the company, according to the SEC ...
Memorial Day: The overlooked military suicide prevention tool no one is talking about
The Washington Times· 4 days agoIndoctrination during medical education can be so powerful that professionals will believe the...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoSequencing Kits Market to be Worth $25.29 Billion by 2031 - Exclusive Report by Meticulous Research® PR Newswire REDDING, Calif., May 21, 2024 REDDING, Calif., May 21, 2024 /PRNewswire/ -- According to a new market research report titled, "Sequencing
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at...
WKRN Nashville· 2 days agoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA ...
Hims & Hers shares maintain Hold on the expansion of weight loss program By Investing.com
Investing.com· 4 days ago(NYSE:HIMS), with a steady stock price target of $13.00, following the company's announcement...
